CompoAtlas

NICODERM(R) 7 mg Step 3

Testo originale in francese.

Prodotto naturale per la salute autorizzato in Canada

L’analisi delle dosi orali non si applica senza una via esclusivamente orale accertata.

Composizione

Composizione medicinale non indicata.

Ingredienti non medicinali

Polyisobutylene, Ethylene Vinyl Acetate, Poly(ester)-1, Polyethylene, Polyethylene terephthalate

Dosi raccomandate in Canada

PopolazioneEtàQuantità per assunzioneFrequenza
AdultesNon précisée1 patch1 Tous les jours

Usi autorizzati in Canada

NICODERM(R) 7 mg Step 3 patch is a medicine that can help you stop smoking by reducing withdrawal symptoms and nicotine cravings. NICODERM(R) provides a lower level of nicotine to your blood than cigarettes, and allows you to gradually do away with your body's need for nicotine. It works as a temporary aid to help you quit smoking by reducing nicotine cravings and nicotine withdrawal symptoms such as irritability, frustration, anxiety, difficulty concentrating and restlessness. Without these powerful urges for the cigarettes you "need", getting rid of the "habit" cigarettes becomes much easier. NICODERM(R) provides 24 hour rate-controlled delivery of nicotine following its application to intact skin. NICODERM(R) reduces the withdrawal symptoms associated with smoking cessation and thus increases the success rate of smoking cessation programs. NICODERM(R) is the only patch that has a rate controlling membrane, to give your body a steady supply of nicotine to help protect you against cravings. Following the first NICODERM(R) application, the plasma nicotine concentration rises rapidly, plateaus within 2 to 4 hours and then slowly declines until the system is removed; after which it declines more rapidly. Nicotine in the adhesive layer is absorbed into and through the skin, causing the initial rapid rise in plasma concentration. The nicotine from the reservoir is released slowly through the membrane with a constant release rate. The rate of release of nicotine from the NICODERM(R) 7 mg/24 hour patch is 0.5 mg/hr. Following the second daily NICODERM(R) system application, steady state plasma nicotine concentration is achieved and is on average 30% higher compared with single dose applications. The quit rate for NICODERM(R) 7 mg/day was 48%. The unique feature offers 24-hour protection, even against the early morning cravings many people find the most difficult.

Testo originale in inglese.

Combination Nicotine Replacement Therapy - Nicoderm(R) patch + as needed Nicorette(R) gum/lozenge/oral inhaler/ oral mist versus mono Nicotine Replacement Therapy is: - Clinically proven to increase your chances of quitting - A clinically proven approach to increase your chances of quitting for good. -If you have a relapse or experience tough/intense cravings or failed with the patch alone, you can use the patch with as needed Nicorette(R) gum/lozenge/oral inhaler/oral mist at the same time to increase your chances of quit success. - Now you can have the combined support of NICODERM(R) patch and NICORETTE(R) as needed gum/lozenge, oral inhaler/ oral mist products together, for a successful quit - Tackle cravings: NICODERM(R) (patch) for slow release constant support and NICORETTE(R) as needed (gum/lozenge, oral inhaler/ oral mist) for an extra quick fix/dose when you really need to fight back the cravings / when something triggers intense cravings. - Combination therapy is 30%/1.3x more effective than using one Nicotine Replacement Therapy product alone - Use NICODERM® patch + NICORETTE® (gum/lozenge/inhaler/oral mist) together to increase your chance of quitting

Testo originale in inglese.

Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.

Avvertenze in Canada

Known Adverse Reactions : Minor skin irritations, headache, light-headedness, insomnia, stomach upset and vivid dream. Allergic reactions (including symptoms of anaphylaxis) occur rarely during use.

Testo originale in inglese.

Scheda del prodotto

Titolare
Kenvue Canada Inc.
NPN o DIN-HM
80044518
Stato
Licenza attiva
Data della licenza
30 agosto 2013
Data di revisione
29 luglio 2024
Forma
Timbre transdermique
Via di somministrazione
Transdermique
Tipo di domanda
Non traditionnelle

Fonte

Scheda ufficiale Health Canada, licenza 80044518

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Testo originale in inglese.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Testo originale in francese.

La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.

Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).

Fotografare la confezione

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Elenco rilevato nel 2024. Fotografi la confezione per verificare eventuali modifiche.

Invio per analizzare, Maiusc+Invio per una nuova riga